The transaction values Penumbra at $374 per share, representing a roughly $14.5 billion enterprise value. Penumbra shareholders may elect to receive cash or Boston Scientific stock, with proration ...
Penumbra offers compelling growth in mechanical thrombectomy, with strong recent results and expanding addressable markets in pulmonary embolism and neurovascular. PEN’s STORM-PE and CLOSABLE studies ...
Physicians in Europe now have access to Penumbra’s most advanced mechanical thrombectomy technology available, which has had a significant impact on patients in the U.S. Designed for single session ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results